Efficacy of Kinetic Oscillation Stimulation for the preventive treatment of chronic migraine



Jan Hoffmann^{1,2}, Holger Kaube³, Florian Rimmele⁴, Tim P. Jürgens^{4,5}, Markku Nissilä⁶, Charly Gaul⁷, Mikko Kallela⁸, Petra Keski-Säntti⁹, Marja-Liisa Sumelahti¹⁰, Andreas Straube¹¹, David Lewis¹², Arne May¹³

CHORDATE

¹Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; ²NIHR-Wellcome Trust King's Clinical Research Facility/SLaM Biomedical Research Centre, King's College Hospital, London, UK; ³Neurologie und Kopfschmerzzentrum Münchner Freiheit, Munich, Germany; ⁴Department of Neurology, Headache Center North-East, University Medical Center Rostock, Rostock, Germany, ⁵Department of Neurolgy, KMG Hospital Güstrow, Güstrow, Germany, ⁶Clinical Research and Biobank, Terveystalo Turku Pulssi, Turku, Finland, ⁷Headache Center Frankfurt, Frankfurt am Main, Germany, ⁸Department of Neurosciences, University of Helsinki, Helsinki, Finland, ⁹Terveystalo Ruoholahti, Helsinki, Finland, ¹⁰Terveystalo Tampere, Tampere, Finland, ¹¹Department of Neurology, University Hospital, LMU Munich, Munich, Germany; ¹²Lewis Neurologie, Stuttgart, Germany; ¹³Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Introduction

Conclusions

- The trigemino-autonomic reflex and parasympathetic outflow play a significant role in migraine pathophysiology¹.
- Parasympathetic neuropeptides such as PACAP and VIP can trigger migraine attacks suggesting along with preclinical data that modulating parasympathetic outflow may provide an effective treatment target^{2,3,4}.
- •Kinetic Oscillation Stimulation (K.O.S) with the Chordate system in the nasal cavity provides a robust activation of the parasympathetic outflow causing cranial autonomic symptoms such as lacrimation⁵.

Aim

To investigate the clinical efficacy of K.O.S for the preventive treatment of chronic migraine.

Methods

- Data represents the results of a multicentre, randomised, shamcontrolled clinical trial (PM007, NCT03400059).
- K.O.S stimulation (85Hz, 80 mbar) or sham stimulation (0Hz, 30 mbar) were conducted for 10 min per nostril 1x per week over a period of 6 weeks.


- •The trial shows that K.O.S is an effective and safe option for the preventive treatment of chronic migraine.
- •K.O.S offers a valuable non-pharmacologic treatment option with a more favourable side effect profile compared to systemic treatments.

Results

- 1. K.O.S significantly reduced the number of MHD with moderate to severe intensity from baseline when compared to sham stimulation (Figs. 3A, 3B).
- 2. The effect was sustained during the 4-week post-treatment follow-up period (Figs. 3A, 3B).
- 3. K.O.S sigificantly reduced the number of monthly migraine days from baseline when compared to sham stimulation (Figs. 4A, 4B).
- 4. A ≥30% reduction in MHD with moderate to severe intensity from baseline was achieved in 47.1% of patients using K.O.S vs. 25.4% using sham (Fig. 5).
- 5. No serious adverse events occurred during the study.

A run-in period Primary endpoint Secondary endpoint (treatment Change from Baseline to Change from Baseline

- **Primary endpoint**: Mean change from baseline in monthly headache days (MHD) with moderate to severe intensity in 4-week performance assessment period.
- •Secondary endpoints included the mean change from baseline in MHD with moderate to severe intensity in 4-week follow-up period, the change in monthly migraine days in assessment and follow-up periods, and the 30% responder rate.






Figure 3: Fig. 3A shows the least square means (LSQ) change in **headache days with moderate to severe in-tensity (MHD)** from baseline to treatment weeks 3-6 and follow-up period. Fig. 3B depicts therapeutic gain.





Figure 2: (A) K.O.S controlling unit (Chordate S211), (B) Nasal stimulation catheter.

time (weeks)

Figure 4: Fig. 4A shows the LSQ change in migraine days from baseline. Fig. 4B depicts the therapeutic gain.



References

Medical AB.

Goadsby *et al.* Physiol Rev 2017; 97: 553-622
Schytz *et al.* Brain 2009; 132: 16-25
Hoffmann *et al.* Pain 2020; 161: 1670-1681
Akerman *et al.* Sci Transl Med 2015; 7(308): 308ra157
Möller *et al.* Cephalalgia 2018; 38(8): 1498-1502

The study has been sponsored by Chordate

Figure 5: 30% responder rate of MHD reduction.

Rev. 02/2024